David Crockett, MD
Internal Medicine · Omaha, NENPI 1801107636
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (51.5%), food and beverage and education — rather than concentrated in one kind of arrangement. Hoffmann-la Roche Limited accounts for 69.0% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2019 at $1,560 and has fallen 95.5% since, to $70 in 2025.
Across 36 payments — averaging $60.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Hoffmann-la Roche Limited$1K
- Aimmune Therapeutics, Inc.$152
- AbbVie$110
- E.r. Squibb & Sons, L.L.C.$46
- Sanofi$43
- Genentech USA, Inc.$40
- plus $279 from 14 others
Across 48 payments — averaging $17,068 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$470K
- Aadi Bioscience, Inc.$146K
- Merck$90K
- Amgen$53K
- Puma Biotechnology, Inc.$43K
- Eli Lilly$11K
- plus $7K from 1 others
What the payments were for
- Travel & lodging$1,11652%
- Food & beverage$98445%
- Education$653%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Hoffmann-la Roche Limited | 3 | $1,494 |
| Aimmune Therapeutics, Inc. | 1 | $152 |
| AbbVie | 5 | $110 |
| E.r. Squibb & Sons, L.L.C. | 3 | $46 |
| Sanofi | 2 | $43 |
| Genentech USA, Inc. | 2 | $40 |
| Amgen | 3 | $37 |
| Pfizer | 2 | $28 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $28 |
| Acrotech Biopharma Inc. | 2 | $28 |
| Merck | 2 | $24 |
| Verity Pharmaceuticals Inc. | 1 | $20 |
| Servier Pharmaceuticals LLC | 1 | $18 |
| Janssen Scientific Affairs, LLC | 1 | $16 |
| Octapharma USA, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Karyopharm Therapeutics Inc. | 1 | $14 |
| Gilead | 1 | $12 |
| Advanced Accelerator Applications | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Non-Covered Product$1,494
- ZENPEP$152
How this compares
$2,165 in reported general payments places this provider in the 85th percentile of 570 internal medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 39 | $518,805 |
| XtandiEnzalutamide | 24 | $327,436 |
| PomalystPomalidomide | 14 | $267,156 |
| JakafiRuxolitinib Phosphate | 12 | $240,071 |
| BrukinsaZanubrutinib | 21 | $221,311 |
| PromactaEltrombopag Olamine | 12 | $158,165 |
| Abiraterone Acetate | 31 | $30,923 |
| EliquisApixaban | 42 | $25,303 |
| XareltoRivaroxaban | 25 | $18,157 |
| Anastrozole | 94 | $1,685 |
| Morphine Sulfate | 12 | $1,661 |
| Hydroxyurea | 45 | $1,468 |
| Fentanyl | 14 | $1,341 |
| Dexamethasone | 65 | $1,267 |
| Levothyroxine Sodium | 102 | $848 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $14 | $327,43624 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $46 | $267,15614 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $16 | $30,92331 claims |
| PfizerEliquis | $28 | $25,30342 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 570 internal medicine providers in Nebraska.
Other internal medicine in Omaha
- Brian BoerOmaha$142K
- Adam BurdorfOmaha$29K
- David SharpOmaha$26K
- David ShinOmaha$26K
- Nikhil JaganOmaha$20K
- Clayton SchroederOmaha$14K
- Ali NayfehOmaha$12K
- Kirtibala GuptaOmaha$12K
- Chad VokounOmaha$11K
- Joel MichalskiOmaha$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.